ALGS Q3 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALGSAligos Therapeutics, Inc.

$45M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$741,000-41.6% YoY

Gross Profit

$741,000100.0% margin

Operating Income

-$28M-3827.4% margin

Net Income

-$32M-4256.0% margin

EPS (Diluted)

$-3.04

QoQ Revenue Growth

-23.2%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$110M

Total Liabilities

$38M

Stockholders' Equity

$72M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$741,000	$1M	-41.6%
Gross Profit	$741,000	$1M	-41.6%
Operating Income	-$28M	-$20M	-40.9%
Net Income	-$32M	-$19M	-63.8%